[HTML][HTML] Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor …

T De Pas, F Toffalorio, M Manzotti, C Fumagalli… - Journal of Thoracic …, 2011 - Elsevier
Introduction Mutations of the epidermal growth factor receptor (EGFR) have been proven to
predict activity of the EGFR-tyrosine kinase inhibitors (EGFR-TKI), gefitinib and erlotinib …

Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non–small cell lung cancer treated with epidermal growth …

PA Jänne, BE Johnson - Clinical cancer research, 2006 - AACR
Somatic mutations in the epidermal growth factor receptor (EGFR) have been identified in
patients with advanced non–small cell lung cancer who achieve dramatic clinical and …

Effectiveness of tyrosine kinase inhibitors on “uncommon” epidermal growth factor receptor mutations of unknown clinical significance in non–small cell lung cancer

JY Wu, CJ Yu, YC Chang, CH Yang, JY Shih… - Clinical cancer …, 2011 - AACR
Purpose: Clinical features of epidermal growth factor receptor (EGFR) mutations, L858R,
deletions in exon 19, T790M, and insertions in exon 20, in non–small cell lung cancer …

[HTML][HTML] Somatic mutations of the tyrosine kinase domain of epidermal growth factor receptor and tyrosine kinase inhibitor response to TKIs in non-small cell lung …

S Murray, IJ Dahabreh, H Linardou… - Journal of thoracic …, 2008 - Elsevier
Background After the discovery of somatic mutations in the tyrosine kinase domain (exons
18–24) of the epidermal growth factor receptor (EGFR) correlating with responses of non …

Rare and complex mutations of epidermal growth factor receptor, and efficacy of tyrosine kinase inhibitor in patients with non-small cell lung cancer

B Keam, DW Kim, JH Park, JO Lee, TM Kim… - International journal of …, 2014 - Springer
Background There are many complex and rare mutations in the epidermal growth factor
receptor (EGFR) gene in non-small cell lung cancer (NSCLC) other than the two classical …

Uncommon mutation types of epidermal growth factor receptor and response to EGFR tyrosine kinase inhibitors in Chinese non-small cell lung cancer patients

K Chen, X Yu, H Wang, Z Huang, Y Xu, L Gong… - Cancer Chemotherapy …, 2017 - Springer
Purpose Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) is the
standard therapy for advanced lung adenocarcinomas with common EGFR mutations …

Uncommon epidermal growth factor receptor mutations in non-small cell lung cancer and their mechanisms of EGFR tyrosine kinase inhibitors sensitivity and …

E Massarelli, FM Johnson, HS Erickson, II Wistuba… - Lung Cancer, 2013 - Elsevier
Therapy targeted against the epidermal growth factor receptor (EGFR) has demonstrated
dramatic tumor responses and favorable clinical outcomes in a select group of non-small …

Efficacy analysis of tyrosine kinase inhibitors on rare non-small cell lung cancer patients harboring complex EGFR mutations

L Peng, ZG Song, SC Jiao - Scientific reports, 2014 - nature.com
The efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI) in
patients with non-small cell lung cancer (NSCLC) is related to EGFR mutations. Although the …

[HTML][HTML] Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors

S Kobayashi, HM Canepa, AS Bailey… - Journal of Thoracic …, 2013 - Elsevier
Background: Non–small-cell lung cancers (NSCLCs) containing EGFR mutations are
exquisitely sensitive to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors …

Effectiveness of tyrosine kinase inhibitors in Japanese patients with non-small cell lung cancer harboring minor epidermal growth factor receptor mutations: results …

T Otsuka, M Mori, Y Yano, J Uchida… - Anticancer …, 2015 - ar.iiarjournals.org
Aim: Non-small cell lung cancer (NSCLC) with minor mutations in the epidermal growth
factor receptor (EGFR) gene, except for the common 15 base-pair deletions in exon 19 and …